Involving an assembled team of experienced scientists and entrepreneurs exploring new frontiers of biology, Octant personnel are applying next-generation DNA sequencing, gene synthesis, and gene editing with the objective of radically changing the drug discovery in the quest for safer, more effective, and cheaper drugs. The firm is usefully understood as a therapeutics company integrating novel and scaled experimental technologies (multiplexed measurements and high-throughput synthetic chemistry) with computation to solve complex challenges in drug discovery. Utilizing synthetic biology and/or the engineering of cells at scale, as a tool for drug discovery, the effort is precisely to engineer human cells to report on the activity of biochemical and physiological pathways to learn how to make better drugs. Then theprocess is one of engineering these cells such that millions of experiments canbe run that modulate genetics and chemistries at an experimental scale that matches computational simulation.
